Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers – current evidence and future directions

Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers – current evidence and future directions

Advances in Next Generation Sequencing (NGS) technologies have enabled the accurate detection and quantification of circulating tumor-derived (ct)DNA in most gastrointestinal (GI) cancers. The prognostic and predictive utility of ctDNA in patiets with different stages of colorectal (CRC), gastro-eso...

Full description

Bibliographic Details
Main Authors:	Rachel C. T. Lam, David Johnson, Gigi Lam, Michelle L. Y. Li, Joyce W. L. Wong, W. K. Jacky Lam, K. C. Allen Chan, Brigette Ma
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Oncology
Subjects:	ctDNA gastrointestinal cancer minimal residual disease prognostic and predictive biomarker next generation sequencing
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.970242/full

Similar Items

Re: Molecular testing to deliver personalised chemotherapy recommendations
by: Peter Gibbs, et al.
Published: (2023-09-01)

Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios
by: Karam Khaddour, et al.
Published: (2022-11-01)

The current state of molecular profiling in gastrointestinal malignancies
by: Reetu Mukherji, et al.
Published: (2022-06-01)

The potential role of minimal/molecular residual disease in colorectal cancer: curative surgery, radiotherapy and beyond
by: Meiyi Xu, et al.
Published: (2023-09-01)

Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients
by: Huu Thinh Nguyen, et al.
Published: (2022-12-01)

Liquid biopsy into the clinics: Current evidence and future perspectives
by: Myrto Boukovala, et al.
Published: (2024-06-01)

Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer
by: Xiaoxu Fang, et al.
Published: (2022-10-01)

Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer
by: Naing Lin Shan, et al.
Published: (2024-12-01)

Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late
by: Maarten J. IJzerman, et al.
Published: (2021-01-01)

Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients
by: Daan C. L. Vessies, et al.
Published: (2022-07-01)

Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
by: Ana Jiménez-Ubieto, et al.
Published: (2023-06-01)

Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
by: Ana Jiménez-Ubieto, et al.
Published: (2024-01-01)

Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
by: Ana Jiménez-Ubieto, et al.
Published: (2023-08-01)

Methylated circulating tumor DNA as a biomarker in cutaneous melanoma
by: Russell J Diefenbach, et al.
Published: (2020-09-01)

The role of circulating tumor DNA in melanomas of the uveal tract
by: Mohammed Zeeshan Zameer, et al.
Published: (2024-12-01)

Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naïve Metastatic Lung Adenocarcinoma
by: Szu-Chun Yang, et al.
Published: (2022-05-01)

Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018
by: Faisal Shahjehan, et al.
Published: (2019-05-01)

Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages
by: Brittany A. McKelvey, et al.
Published: (2024-04-01)

Postoperative circulating tumor DNA testing based on tumor naïve strategy after liver metastasis surgery in colorectal cancer patients
by: Huiqin Jiang, et al.
Published: (2023-04-01)

Circulating tumor DNA as prognostic markers of relapsed breast cancer: a systematic review and meta-analysis
by: Na'na Guo, et al.
Published: (2024-03-01)

Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study
by: Rui Fu, et al.
Published: (2023-05-01)

Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study
by: Arnaud Bayle, et al.
Published: (2023-11-01)

Exploring the Clinical Value of Perioperative ctDNA‐Based Detection of Molecular Residual Disease in Patients With Esophageal Squamous Cell Carcinoma
by: Jimin Li, et al.
Published: (2025-02-01)

Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER
by: E. Smyth, et al.
Published: (2024-12-01)

Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments
by: Youjin Oh, et al.
Published: (2024-05-01)

Stool and blood biomarkers for colorectal cancer management: an update on screening and disease monitoring
by: Alessandro Mannucci, et al.
Published: (2024-11-01)

Liquid biopsy for monitoring minimal residual disease in localized and locally-advanced non-small cell lung cancer after radical-intent treatment
by: Héctor Aguilar, et al.
Published: (2024-06-01)

Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis
by: Lucie Benesova, et al.
Published: (2022-06-01)

Benchmarking UMI-aware and standard variant callers for low frequency ctDNA variant detection
by: Rugare Maruzani, et al.
Published: (2024-09-01)

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
by: Estela Sánchez-Herrero, et al.
Published: (2022-07-01)

The utilisation of ctDNA approaches for residual disease detection during neoadjuvant and perioperative immunotherapy in oesophagogastric cancers
by: Ronan J. Kelly, et al.
Published: (2025-02-01)

Circulating Tumor DNA Testing Supports Rapid Therapeutic Decision-Making in Metastatic Melanoma: A Case Report
by: Tapas Ranjan Behera, et al.
Published: (2022-06-01)

From haystack to high precision: advanced sequencing methods to unraveling circulating tumor DNA mutations
by: Tamires Ferreira da Silva, et al.
Published: (2024-08-01)

Novel imaging and circulating biomarkers in hepatic malignancies
by: Winter, H
Published: (2019)

Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study
by: Hesong Wang, et al.
Published: (2024-01-01)

Circulating tumour cell enumeration, biomarker analyses, and kinetics in patients with colorectal cancer and other GI malignancies
by: Walla Malkawi, et al.
Published: (2023-11-01)

Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma
by: Sonu Kumar, et al.
Published: (2023-08-01)

Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcomaResearch in context
by: Yiwei Fu, et al.
Published: (2024-07-01)

mFast‐SeqS‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer
by: Khrystany T. Isebia, et al.
Published: (2023-09-01)

Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer
by: Fulong Wang, et al.
Published: (2023-12-01)